secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2026-06-03T20:17:06+00:00
Accession:  0000950103-26-008465
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics: LOTIS-5 Phase 3 meets PFS endpoint; sBLA submission planned Q4 2026
--------------------------------------------------------------------------------

- PFS HR=0.73 (p=0.008); median PFS 6.1 mo ZYNLONTA+ritux vs 4.7 mo R-GemOx.
- ORR 58.1% vs 45.2%; CR 39.5% vs 26.7%; median DoCR 16.8 vs 12.3 mo.
- Grade 5 TEAEs higher in test arm (13.2% vs 4.6%); majority in patients ≥75 years.
- Plans pre-sBLA meeting with FDA in August; sBLA submission expected Q4 2026.
- Company will evaluate value-maximizing alternatives, including cost reduction initiatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000095010326008465/0000950103-26-008465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000095010326008465/dp247928_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-26-008465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer